Valkyrie Clinical Trials

Los Angeles, CA

Sorting 1 by

Accepting patients

IDP-023

Phase 1/2 Study of IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
Learn more
  • Natural Killer Cells (Allogeneic)
  • Phase 1/2